[Clinical study on the use of SB 5833 (Camazepam) in general medicine].
D000328:Adult; D000469:Alkaline Phosphatase / Q000378:metabolism; D014151:Anti-Anxiety Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy; D001552:Benzazepines / Q000494:pharmacology / Q000627:therapeutic use; D001569:Benzodiazepines; D001663:Bilirubin / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D001797:Blood Protein Electrophoresis; D002302:Cardiac Output / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000378:metabolism; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011602:Psychophysiologic Disorders / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism; D011674:Pulse / Q000187:drug effects; D012890:Sleep / Q000187:drug effects; D000637:Transaminases / Q000378:metabolism
D014151:Anti-Anxiety Agents; D001552:Benzazepines; D001569:Benzodiazepines; D003404:Creatinine; D000637:Transaminases; D000469:Alkaline Phosphatase; D001663:Bilirubin
Studio clinico sull'uso del SB 5833 (Camazepam) in medicina generale